PMID- 38408767
OWN - NLM
STAT- Publisher
LR  - 20240226
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
DP  - 2024 Feb 26
TI  - Prevalence of potentially inappropriate medications among newly treated patients 
      with type 2 diabetes in UK primary care.
LID - 10.1111/bcp.16018 [doi]
AB  - AIMS: The aim of this study was to estimate the prevalence of potentially 
      inappropriate prescriptions (PIPs) in patients starting their first noninsulin 
      antidiabetic treatment (NIAD) using two explicit process measures of the 
      appropriateness of prescribing in UK primary care, stratified by age and 
      polypharmacy status. METHODS: A descriptive cohort study between 2016 and 2019 
      was conducted to assess PIPs in patients aged >/=45 years at the start of their 
      first NIAD, stratified by age and polypharmacy status. The American Geriatrics 
      Society Beers criteria 2015 was used for older (>/=65 years) patients and the 
      Prescribing Optimally in Middle-age People's Treatments criteria was used for 
      middle-aged (45-64 years) patients. Prevalence of overall PIPs and individual 
      PIPs criteria was reported using the IQVIA Medical Research Data incorporating 
      THIN, a Cegedim Database of anonymized electronic health records in the UK. 
      RESULTS: Among 28 604 patients initiating NIADs, 18 494 (64.7%) received 
      polypharmacy. In older and middle-aged patients with polypharmacy, 39.6% and 
      22.7%, respectively, received >/=1 PIP. At the individual PIP level, long-term 
      proton pump inhibitors (PPI) use was the most frequent PIP among older adults, 
      and strong opioid without laxatives was the most frequent PIP in middle-aged 
      patients with polypharmacy (11.1% and 4.1%, respectively). CONCLUSIONS: This 
      study revealed that patients starting NIAD treatment receiving polypharmacy have 
      the potential for pharmacotherapy optimization.
CI  - (c) 2024 The Authors. British Journal of Clinical Pharmacology published by John 
      Wiley & Sons Ltd on behalf of British Pharmacological Society.
FAU - Faquetti, Maria Luisa
AU  - Faquetti ML
AUID- ORCID: 0000-0002-5990-3322
AD  - Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Zurich, 
      Switzerland.
FAU - Frey, Geraldine
AU  - Frey G
AD  - Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Zurich, 
      Switzerland.
FAU - Stampfli, Dominik
AU  - Stampfli D
AUID- ORCID: 0000-0001-5293-134X
AD  - Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Zurich, 
      Switzerland.
AD  - Hospital Pharmacy, Kantonsspital Baden, Baden, Switzerland.
FAU - Weiler, Stefan
AU  - Weiler S
AUID- ORCID: 0000-0003-1087-7597
AD  - Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Zurich, 
      Switzerland.
FAU - Burden, Andrea M
AU  - Burden AM
AUID- ORCID: 0000-0001-7082-8530
AD  - Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Zurich, 
      Switzerland.
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20240226
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
SB  - IM
OTO - NOTNLM
OT  - diabetes mellitus type 2
OT  - inappropriate medication
OT  - inappropriate prescribing
OT  - polypharmacy
OT  - potentially inappropriate medication list
OT  - primary healthcare
EDAT- 2024/02/27 00:42
MHDA- 2024/02/27 00:42
CRDT- 2024/02/26 20:43
PHST- 2024/01/17 00:00 [revised]
PHST- 2023/09/25 00:00 [received]
PHST- 2024/01/19 00:00 [accepted]
PHST- 2024/02/27 00:42 [medline]
PHST- 2024/02/27 00:42 [pubmed]
PHST- 2024/02/26 20:43 [entrez]
AID - 10.1111/bcp.16018 [doi]
PST - aheadofprint
SO  - Br J Clin Pharmacol. 2024 Feb 26. doi: 10.1111/bcp.16018.